Concepedia

Heidi Kabler

HK

Statistics

Publications

8

Citations

1.4K

H-Index

8

Active since

2014

Affiliations

Doctors Company (United States)(Current)

Gilead Sciences (United States)

Sunrise Hospital & Medical Center

Precision Research Institute

Duke Medical Center

Heidi Kabler is an author at Doctors Company (United States) specializing in pharmacotherapy, pharmacology, and treatment of skin infections.

ORCID

Publications per year

2014–2022

8

Publications

8

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

, , +12

Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections

G. Ralph Corey, Heidi Kabler, Purvi Mehra et al. · New England Journal of Medicine · 2014 · 302 citations · Full text

, , +16

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Rohit Loomba, Mazen Noureddin, Kris V. Kowdley et al. · Hepatology · 2020 · 278 citations

, , +17

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

Naim Alkhouri, Robert Herring, Heidi Kabler et al. · Journal of Hepatology · 2022 · 209 citations

, , +16

Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid

Frederick Wittke, Catherine Vincent, James Chen et al. · Antimicrobial Agents and Chemotherapy · 2020 · 57 citations · Full text

, , +17

1–5 of 8